2:00 - 6:30pm [CET]
Several investigational studies of monoclonal antibodies for the prevention of infectious diseases and the treatment of cancer have shown that they are able to enhance the adaptive immune response in addition to providing protective immunity or anti-tumour activity. Various mechanisms of action have been identified, including complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular viral inhibition. In addition, immune complexes formed with different viral elements can be recognized by both activating and inhibitory FcγRs on various cell types, including dendritic cells.
Activating these receptors can stimulate dendritic cells to generate effector T-cells, leading to longer and stronger antiviral immune responses, known as the "vaccinal effect". This vaccinal effect has been observed in a range of conditions, including cancer, influenza, SARS-CoV-2, hepatitis and HIV. However, the Fc-mediated vaccinal effect of monoclonal antibodies (mAbs) is still poorly studied. With the increased role of bnAbs for the prevention and treatment of HIV, understanding the immunological mechanisms driving the induction of the vaccinal effect by mAbs could contribute to the design of effective preventive and therapeutic interventions.
Invite only – if you are interested in this event, you can contact enterprise@iasociety.org